Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapyMark Brantly, Terence R. Flotte, Lili Wang et al.|Proceedings of the National Academy of Sciences|2009Cited by 322
Phase I Safety and Immunogenicity Evaluations of an Alphavirus Replicon HIV-1 Subtype C<i>gag</i>Vaccine in Healthy HIV-1-Uninfected AdultsMargaret Wecker, Donald S. Burke, Peter B. Gilbert et al.|Clinical and Vaccine Immunology|2012Cited by 68
Safety and Biodistribution Evaluation of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin, in RS1-Deficient MiceGuojie Ye, Jeffrey D. Chulay, Thomas J. Conlon et al.|Human Gene Therapy Clinical Development|2015Cited by 29
Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 MiceChunjuan Song, Guojie Ye, Thomas J. Conlon et al.|Human Gene Therapy Clinical Development|2018Cited by 19
463. Safety and Biodistribution Study of rAAV2tYF-CB-hRS1 in RS1-deficient MiceGuo-jie Ye, Jeffrey D. Chulay, Kirsten Erger et al.|Molecular Therapy|2015Cited by 0